Helix CBD Clinical Cream — Class II drug recall D-1093-2023
Terminated recall by Parker Laboratories, Inc., reported 2023-08-30, distributed nationwide. CGMP Deviations
| Recall number | D-1093-2023 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Parker Laboratories, Inc., Fairfield, NJ, United States |
| Recall initiated | 2023-08-02 |
| Classified | 2023-08-18 |
| Reported by FDA | 2023-08-30 |
| Terminated | 2024-06-03 |
| Distributed | Nationwide (US) |
| Countries outside the US | HK, KR, SG |
| Quantity | 50 |
| Reason classes | cgmp |
| NDC | 30775-0054-01, 30775-0054-02, 30775-0054-04 |
| Expiration dates | 2023-08-18, 2023-12-21 |
Product
Helix CBD Clinical Cream (Menthol 7.4%), packaged in a)3 gm pouches (NDC30775-054-01), b)2 fl. oz. tubes (NDC 30775-054-02), and c) 4 fl. oz. tubes (NDC 30775-054-04), Parker Laboratories, Inc. 286 Eldridge Road, Fairfield, NJ 07004
Reason for recall
CGMP Deviations
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1093-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.